The Effects of Focal Vibration on Spasticity in Multiple Sclerosis Patients
The Effects of Focal Vibration on Central and Peripheral Spasticity in Multiple Sclerosis Patients. A Randomized, Multicenter, Double Blinded vs Placebo Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Campania
-
Naples, Campania, Italy, 81025
- Prof. Giuseppe Orefice
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Multiple Sclerosis affected
- Spasticity
- EDSS (Expanded Disability Status Scale) 0 - 5,5
- Patients able to sign informed consent
Exclusion Criteria:
- Age less than 18 years old and more than 65 years old
- Pacemaker
- Pregnancy
- Comorbidities as: cancer, hypertension not controlled by drugs
- concurrent therapies with antidepressant or corticosteroids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Equistasi Group
arm treated with application of devices
|
|
|
Placebo Comparator: Placebo Group
arm treated with application of inactivated devices
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gait Velocity
Time Frame: one year
|
evaluation of gait velocity in m/s
|
one year
|
|
First step length
Time Frame: one year
|
first step length in cm
|
one year
|
|
Swing phase
Time Frame: one year
|
swing phase measured in seconds
|
one year
|
|
Stance phase
Time Frame: one year
|
stance phase measured in seconds
|
one year
|
|
Double support time
Time Frame: one year
|
double support time measured in seconds
|
one year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
H/M ratio
Time Frame: one year
|
evaluation of neurophysiological modifications in treated patients vs placebo group, as ratio between H max and M max in tibial posterior nerve, in Unit
|
one year
|
|
Berg Balance Scale
Time Frame: one year
|
Evaluation of balance with a self administered scale, measured in Unit
|
one year
|
|
Modified Fatigue Scale
Time Frame: one year
|
evaluation of fatigue with a self administered scale, measured in Unit
|
one year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Manifestations
- Muscle Hypertonia
- Multiple Sclerosis
- Sclerosis
- Muscle Spasticity
Other Study ID Numbers
Other Study ID Numbers
- 71/15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
NCT01917019CompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent Progressive
-
NCT05177523RecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)
-
NCT01466114UnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple Sclerosis
-
NCT07006805Not yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
NCT00813969CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple Sclerosis
-
NCT02549703CompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
-
NCT04688788Active, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
-
NCT04940065CompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple Sclerosis
-
NCT02495766CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
-
NCT00559702CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
Clinical Trials on Placebo
-
NCT03827590UnknownAcute Bronchitis | Acute Upper Respiratory Tract Infection
-
NCT02177513Completed
-
NCT02935712CompletedMale Subjects With Type II Diabetes (T2DM)
-
NCT06767540Not yet recruiting
-
NCT03198624CompletedPharmacokinetics | Safety Issues
-
NCT02982187CompletedPulmonary Disease, Chronic Obstructive
-
NCT04693039Completed
-
NCT01610388Completed
-
NCT04388215UnknownHypertension | Dyslipidemias